評估L-carnitine 對中度以上癌因性疲憊的治療效益

注册号:

Registration number:

ChiCTR2400088445 

最近更新日期:

Date of Last Refreshed on:

2024-08-19 17:24:22 

注册时间:

Date of Registration:

2024-08-19 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

評估L-carnitine 對中度以上癌因性疲憊的治療效益

Public title:

Evaluate L-carnitine treatment response in moderate cancer fatigue patients

注册题目简写:

癌因性疲憊的治療

English Acronym:

Treatment of cancer-related fatigue

研究课题的正式科学名称:

評估L-carnitine 對中度以上癌因性疲憊的治療效益

Scientific title:

Evaluate L-carnitine treatment response in moderate cancer fatigue patients

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

劉明宜 

研究负责人:

林家義 

Applicant:

Ming-Yi Liu 

Study leader:

Ka-Ee Ling 

申请注册联系人电话:

Applicant telephone:

+886 933 304 050

研究负责人电话:

Study leader's
telephone:

+886 6 274 8316

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

liumiyi@gmail.com

研究负责人电子邮件:

Study leader's E-mail:

d4039@sinlau.org.tw

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

中國台灣省台南市永康區南台街一號

研究负责人通讯地址:

中國台灣省台南市東區東門路一段57號

Applicant address:

No.1, Nantai St., Yungkang Dist., Tainan City, Taiwan, China

Study leader's address:

No. 57, Sec. 1, Dongmen Rd., Tainan City, Taiwan, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

南臺科技大學

Applicant's institution:

Southern Taiwan University of Science and Technology

研究负责人所在单位:

台南新樓醫院

Affiliation of the Leader:

Tainan Sin-Lau Hospital

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

SLH-113-A-001

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

台南新樓醫院人體研究倫理審查委員會

Name of the ethic committee:

Institutional. Review Board of Tainan Sin-Lau Hospital

伦理委员会批准日期:

Date of approved by ethic committee:

2024-07-08 00:00:00

伦理委员会联系人:

蔡耀隆

Contact Name of the ethic committee:

Yao-Long Tsai

伦理委员会联系地址:

中國台灣省台南市東區東門路一段57號

Contact Address of the ethic committee:

No. 57, Sec. 1, Dongmen Rd., Tainan City, Taiwan, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+886 6 274 8316

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

台南新樓醫院

Primary sponsor:

Tainan Sin-Lau Hospital

研究实施负责(组长)单位地址:

中國台灣省台南市東區東門路一段57號

Primary sponsor's address:

No. 57, Sec. 1, Dongmen Rd., Tainan City, Taiwan, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中國

省(直辖市):

台灣

市(区县):

台南市

Country:

China

Province:

Taiwan

City:

Tainan

单位(医院):

台南新樓醫院

具体地址:

中國台灣省台南市東區東門路一段57號

Institution
hospital:

Tainan Sin-Lau Hospital

Address:

No. 57, Sec. 1, Dongmen Rd., Tainan City, Taiwan, China

经费或物资来源:

自籌

Source(s) of funding:

NO

研究疾病:

癌症  

Target disease:

Cancer, Neoplasm

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

单臂 

Study design:

Single arm 

研究目的:

(一) 評估L-carnitine 對中度以上癌因性疲憊的治療效益 (二) 評估癌症病人蛋白質攝取量對癌因性疲憊的影響 (三) 評估癌因性疲憊對癌症病人的日常生活品質影響  

Objectives of Study:

1. Assessing the Therapeutic Benefits of L-Carnitine for Moderate to Severe Cancer-Related Fatigue 2. Evaluating the Impact of Protein Intake in Cancer Patients on Cancer-Related Fatigue 3. Assessing the Impact of Cancer-Related Fatigue on the Daily Quality of Life of Cancer Patients

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1. 無法或不願意接受靜脈注射的病人 2. 對L-carnitine過敏者 3. 曾有癲癇發作過病人 4. 重度憂鬱 5. 懷孕或哺乳期的病人

Exclusion criteria:

1. Patients who are unable or unwilling to receive intravenous injections. 2. Individuals allergic to L-carnitine. 3. Patients with a history of seizures. 4. Severe depression. 5. Pregnant or breastfeeding patients.

研究实施时间:

Study execute time:

From 2024-09-01 00:00:00 To 2024-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-09-01 00:00:00 To 2024-10-31 00:00:00

干预措施:

Interventions:

组别:

實驗組

样本量:

30

Group:

intervention group

Sample size:

干预措施:

在實驗期間,每位受試者接受靜脈輸注L-carnitine治療, 每周三次, 每次1g。於兩周治療結束後再評估其疲備量尺分數和生活品質是否有改善。

干预措施代码:

Intervention:

During the experiment, each subject received intravenous infusion of L-carnitine, three times a week, 1g each time. After two weeks of treatment, assess whether there has been any improvement in fatigue scale scores and quality of life.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中國

省(直辖市):

台灣 

市(区县):

台南市 

Country:

China

Province:

Taiwan

City:

Tannan

单位(医院):

台南新樓醫院 

单位级别:

N/A 

Institution
hospital:

Tainan Sin-Lau Hospital

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

台灣版簡明疲憊量表

指标类型:

主要指标

Outcome:

BFI- Taiwan Form

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

病人整體營養狀況評估表

指标类型:

主要指标

Outcome:

Patient Generated-Subjective Global Assessment

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

血液

组织:

Sample Name:

Blood

Tissue:

人体标本去向

使用后销毁  

说明

Fate of sample:

Destruction after use  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 20 years
最大 Max age 85 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

None

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

None

Blinding:

None

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

數據資料可於2025年6月30日以後向台南新樓醫院林家義醫師申請(e-mail: d4039@sinlau.org.tw)

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

Data can be applied to Dr. Lin of Tainan Sinlau Hospital after June 30,2025(e-mail: d4039@sinlau.org.tw)

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表/电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

Case Record Form/Electronic Data Capture

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-08-19 17:24:03